206 studies found for:    nash
Show Display Options
RSS Create an RSS feed from your search for:
nash
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
Condition: Non-Alcoholic Steatohepatitis
Intervention:
2 Recruiting Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab 700mg;   Biological: Simtuzumab 200mg;   Biological: Placebo
3 Unknown  Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)
Condition: Metabolic Parameters and Liver Histology
Interventions: Drug: Pioglitazone;   Drug: Pentoxifylline
4 Completed The Role of Leptin Receptors in NASH
Conditions: Nonalcoholic Steatohepatitis;   Metabolic Syndrome
Intervention: Other: no interventions, only regular blood-draw
5 Completed The Effect of Protandim on Non-alcoholic Steatohepatitis
Condition: Non-Alcoholic Steatohepatitis
Interventions: Dietary Supplement: Protandim;   Dietary Supplement: Placebo
6 Terminated
Has Results
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Steatohepatitis (NASH);   Hepatic Steatosis
Interventions: Drug: Omega-3-acid ethyl esters (Lovaza);   Drug: Placebo
7 Completed Omega 3 Supplementation in Fatty Liver
Condition: Fatty Liver
Intervention: Dietary Supplement: Omega 3
8 Unknown  Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
Conditions: Nonalcoholic Steatohepatitis;   Liver Diseases
Intervention: Drug: Pentoxifylline
9 Recruiting Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: placebo;   Drug: pioglitazone;   Dietary Supplement: Vitamin E
10 Active, not recruiting The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Conditions: Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: obeticholic acid;   Drug: placebo
11 Active, not recruiting Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Condition: Non Alcoholic Fatty Liver Diseases (NAFLD)
Intervention:
12 Enrolling by invitation Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GR-MD-02;   Drug: Placebo
13 Completed Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
Condition: Non-Alcoholic Steatohepatitis(NASH)
Interventions: Drug: Active treatment;   Drug: Placebo
14 Active, not recruiting Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GFT505 80mg;   Drug: GFT505 120mg;   Drug: Placebo
15 Completed Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
Conditions: Non-alcoholic Steatohepatitis;   Fatty Liver
Interventions: Drug: Omega 3 Fish Oil supplements;   Drug: Placebo
16 Recruiting Simtuzumab (GS-6624) in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab 75 mg;   Biological: Simtuzumab 125 mg;   Biological: Placebo
17 Completed Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Intervention: Drug: TRO19622
18 Completed Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
Conditions: Hepatic Cirrhosis;   Nonalcoholic Steatohepatitis
Intervention: Drug: NRL972
19 Terminated An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
Condition: Fatty Liver
Interventions: Drug: rimonabant (SR141716);   Drug: Placebo
20 Terminated An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
Condition: Fatty Liver
Interventions: Drug: rimonabant (SR141716);   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years